Table 3.
Network meta-analysis: OS (HR, 95% CI and p-values are shown).
| Cemiplimab | Atezolizumab | Pembrolizumab (KN-024/KN-042) |
Durvalumab | |
|---|---|---|---|---|
| Atezolizumab | 0.97 (0.58–1.60) p = 0.893 |
|||
|
Pembrolizumab
(KN-024/KN-042) |
0.84 (0.59–1.19) p = 0.319 |
0.87 (0.58–1.29) p = 0.483 |
||
| Durvalumab | 0.75 (0.48–1.16) p = 0.199 |
0.78 (0.47–1.29) p = 0.331 |
0.90 (0.63–1.30) p = 0.578 |
|
| Nivolumab | 0.63 (0.40–1.01) p = 0.056 |
0.66 (0.38–1.12) p = 0.123 |
0.76 (0.51–1.12) p = 0.166 |
0.84 (0.52–1.36) p = 0.484 |
Note: The table must be read as the drug in the column against the drug in the row. For example, the OS HR of cemiplimab against atezolizumab is 0.97 (95% CI 0.58, 1.60). KN, KEYNOTE.